Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
BMRN > SEC Filings for BMRN > Form 8-K on 6-Mar-2014All Recent SEC Filings




Entry into a Material Definitive Agreement, Other Events, Financial S

Item 1.01 Entry into a Material Definitive Agreement.

On March 4, 2014, BioMarin Pharmaceutical Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Merrill Lynch, Pierce, Fenner & Smith Incorporated (the "Underwriter") pursuant to which the Underwriter agreed to purchase 1,500,000 shares (the "Shares") of the Company's common stock, par value $0.001 per share, at a price per share of $78.45 (the "Offering"), which will result in net proceeds to the Company of $117.7 million, before deducting estimated offering expenses payable by the Company. The Offering is expected to close on or about March 10, 2014, subject to customary closing conditions, including receipt of legal opinions and approval of legal matters by counsel to the Underwriter. The Shares will be listed on the NASDAQ Global Select Market.

The Underwriting Agreement includes customary representations, warranties and covenants by the Company and customary conditions to closing, obligations of the parties and termination provisions. Additionally, under the terms of the Underwriting Agreement, the Company has agreed to indemnify the Underwriter against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute to payments the Underwriter may be required to make in respect of these liabilities.

The Offering was made pursuant to the Company's Registration Statement on Form S-3 (Registration No. 333-191604) (the "Registration Statement"), which became effective October 7, 2013, and the prospectus dated October 7, 2013 included in the Registration Statement, as supplemented by a prospectus supplement dated March 4, 2014.

The summary of the Underwriting Agreement is qualified in its entirety by reference to the full text of the Underwriting Agreement, which is filed as Exhibit 1.1 hereto and is incorporated herein by reference.

Item 8.01 Other Events.

In connection with the Offering, the Company is filing the opinion and consent of its counsel, Paul Hastings LLP, regarding the validity of the securities being registered as Exhibits 5.1 and 23.1 hereto, respectively.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 1.1     Underwriting Agreement, dated March 4, 2014, by and between
                BioMarin Pharmaceutical Inc. and Merrill Lynch, Pierce, Fenner &
                Smith Incorporated.

Exhibit 5.1     Opinion of Paul Hastings LLP.

Exhibit 23.1    Consent of Paul Hastings LLP (included in its opinion filed as
                Exhibit 5.1 hereto).

  Add BMRN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for BMRN - All Recent SEC Filings
Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.